Abstract
During the organogenic period of development the cardiovascular system of the embryo fulfills several functions including delivery of oxygen and nutrients and a hemodynamic role necessary for cardiac morphogenesis, angiogenesis and hematopoiesis. It is expected that at each stage of embryonic development there is an ideal embryonic heart rate and contractility that maintains the optimal blood flow and pressure to fulfill these various functions. In vitro rat embryo culture studies have revealed that many therapeutic drugs (antiarrhythmics, antidepressants, antipsychotics and anticonvulsants), that may be taken during human pregnancy, cause a concentrationdependent slowing of the embryonic heart and irregular heart rate at higher concentrations. The concentrations causing bradycardia in vitro are often close to human therapeutic plasma concentrations and raise concern that these drugs can potentially cause embryonic death or malformations, and that current reproductive toxicity testing does not adequately examine possible effects of drugs on the embryo’s cardiac function.
Keywords: Bradycardia, arrhythmia, antidepressants, hERG, antipsychotics, pregnancy, first trimester, heart, embryo, fetal, rat, human, cardiac, ion channels.
Current Pharmaceutical Design
Title:Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Volume: 20 Issue: 34
Author(s): William S Webster, Mats Nilsson and Helen Ritchie
Affiliation:
Keywords: Bradycardia, arrhythmia, antidepressants, hERG, antipsychotics, pregnancy, first trimester, heart, embryo, fetal, rat, human, cardiac, ion channels.
Abstract: During the organogenic period of development the cardiovascular system of the embryo fulfills several functions including delivery of oxygen and nutrients and a hemodynamic role necessary for cardiac morphogenesis, angiogenesis and hematopoiesis. It is expected that at each stage of embryonic development there is an ideal embryonic heart rate and contractility that maintains the optimal blood flow and pressure to fulfill these various functions. In vitro rat embryo culture studies have revealed that many therapeutic drugs (antiarrhythmics, antidepressants, antipsychotics and anticonvulsants), that may be taken during human pregnancy, cause a concentrationdependent slowing of the embryonic heart and irregular heart rate at higher concentrations. The concentrations causing bradycardia in vitro are often close to human therapeutic plasma concentrations and raise concern that these drugs can potentially cause embryonic death or malformations, and that current reproductive toxicity testing does not adequately examine possible effects of drugs on the embryo’s cardiac function.
Export Options
About this article
Cite this article as:
Webster S William, Nilsson Mats and Ritchie Helen, Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?, Current Pharmaceutical Design 2014; 20 (34) . https://dx.doi.org/10.2174/1381612820666140205151146
DOI https://dx.doi.org/10.2174/1381612820666140205151146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Status Epilepticus: An Overview
Current Drug Metabolism Chemical Constituents and Biological Significance of the Genus Ilex (Aquifoliaceae)
The Natural Products Journal Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Current Vascular Pharmacology The Role of Dietary Fats in Hypertension, Obesity and Insulin Resistance: A Comparative Study of Animals and Humans in Fetal and Adult Life
Current Nutrition & Food Science Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Genomics and Traditional Chinese Medicine: A New Driver for Novel Molecular-Targeted Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Hydrogen Sulfide Regulates Intracellular Ca2+ Concentration in Endothelial Cells From Excised Rat Aorta
Current Pharmaceutical Biotechnology Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Thoracic Surgical Approaches in the Trauma Setting: A Basic Review
Current Respiratory Medicine Reviews Opioid-induced Cardioprotection
Current Pharmaceutical Design PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials